Effects of tranexamic acid in amount of bleeding in patients with pelvic trauma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130710013947N7

Enrollment

106

Registered

2018-01-12

Start date

2018-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulant drugs. Anticoagulant antagonists, vitamin K and other coagulants

Interventions

Intervention 1: Intervention group: will receive TXA 1for single dose. Intervention 2: Control group: will receive placebo.

Treatment - Drugs

Placebo

Intervention group: will receive TXA 1for single dose

Control group: will receive placebo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with age 18-60 years oldAll the patients with pelvic trauma who admitted in hospital in first 3 hours after accident

Exclusion criteria

Exclusion criteria: Patients who died during the operation or studymultitraumaAnticoagulant drugs use such as A.S.A and dipyridamole; Increased in PT, PTT, INR;History of CVA, MI, bleeding disorder, TBI, CPR, Renal Failure, OCP;Pregnancy and breastfeedingPatients received pack

Design outcomes

Primary

Measure	Time frame
Blood loss. Timepoint: 24hT 48h and 72 h. Method of measurement: based on blood pressure, Hb, Hct, Pulse rate.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Vahid Monsef

Rasht University of Medical Sciences

ajavadir@gmail.com+98 91133335820

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026